Respiratory News and Research

RSS

ERS, ECDC publish European Union Standards for Tuberculosis Care

Today, the European Respiratory Society (ERS) and the European Centre for Disease Prevention and Control (ECDC) publish their jointly developed European Union Standards for Tuberculosis Care.

2 Apr 2012

Cortex reports net income of $832,000 for fourth quarter 2011

Cortex Pharmaceuticals, Inc. reported net income of approximately $832,000, or $0.01 per share, for the quarter ended December 31, 2011, compared with a net loss of approximately $984,000, or $0.01 per share, for the corresponding prior year quarter.

31 Mar 2012

Data from Cempra's CEM-101 Phase 2 trial on CABP to be presented at ECCMID

Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections.

31 Mar 2012

Prenatal, early childhood mechanisms are potential intervention targets for asthma prevention

Children who develop asthma by age seven have deficits in lung function and increased bronchial responsiveness as neonates, a new study from researchers in Denmark suggests.

31 Mar 2012

Physicians advised to use caution in prescribing sedatives for patients taking opioids

Adverse events associated with taking opioid pain medications increase in patients who concurrently use sedatives and alcohol. A study in The Journal of Pain, published by the American Pain Society, advises physicians to use caution in prescribing sedatives for patients taking opioids, even if there is no history of substance abuse.

30 Mar 2012

Needle-free vaccine shows promise against RSV in children

Researchers at the University of Saskatchewan are closing in on a needle-free vaccine for respiratory syncytial virus (RSV), a major cause of respiratory illness in children under two years of age.

30 Mar 2012

Ozone can trigger severe violent breathing attacks in many people

Ozone, the prevalent gas found in air pollution, and mostly experienced from March to October, can trigger severe violent breathing attacks in many people, particularly children and seniors, says a lung expert from Ben Taub General Hospital in Houston.

30 Mar 2012

Lung function changes linked with asthma occur very early in life

Children who develop asthma by age seven have deficits in lung function and increased bronchial responsiveness as neonates, a new study from researchers in Denmark suggests.

30 Mar 2012

Music helps relieve anxiety during surgery: Study

According to research playing music to patients undergoing surgery reduces their anxiety and could improve healing. Easy listening music and chart classics can lessen fear among patients who stay awake during surgery but require a local anesthetic say researchers.

29 Mar 2012

Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint

New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.

29 Mar 2012

COPD Foundation to lead DRIVE4COPD campaign

The successful national campaign to increase public awareness of COPD changed organizational leadership effective March 23, 2012. Led since inception by Boehringer Ingelheim Pharmaceuticals Inc., a leader in developing medicines to treat COPD, the DRIVE4COPD campaign will now be led by the COPD Foundation, a not-for-profit organization dedicated to the education, early diagnosis, research and enhanced therapy for people with lives impacted by COPD.

29 Mar 2012

Stem Cells reports results of Neuralstem ALS Phase I trial

Neuralstem, Inc. announced that safety results from the first 12 patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) to receive its stem cells were reported online in the peer-reviewed publication, Stem Cells, on March 13th.

29 Mar 2012

iSonea launches post-market study of WheezoMeter device for pediatric asthma

Medical technology company, iSonea Ltd. today announced the launch of a post-market study using iSonea's WheezoMeter monitoring technology.

29 Mar 2012

Mylan receives FDA approval for generic Seroquel ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Quetiapine Fumarate Tablets, 25 mg.

29 Mar 2012

Adjusting ventilator to keep breath size and lung pressures lower can reduce death from lung injury

Carefully adjusting mechanical ventilator settings in the intensive care unit to pump smaller breaths into very sick lungs can reduce the chances of dying by as much as 8 percent, according to a study by critical care experts at Johns Hopkins. Study participants were evaluated for two years after their acute lung injury.

28 Mar 2012

Invasive strategy benefits patients with myotonic dystrophy type 1 neuromuscular disorder

Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing of their heart's electrical conduction system and if needed, implantation of a device such as a pacemaker, had an associated higher rate of 9-year survival compared to patients treated noninvasively, according to a study in the March 28 issue of JAMA.

28 Mar 2012

Possible link between sleep apnea and post-surgical delirium

An anecdotal observation of a possible link between sleep apnea and post-surgical delirium has been measured and confirmed by a team of researchers at the Duke University Medical Center.

28 Mar 2012

Surfaxin receives FDA approval for prevention of RDS in premature infants

The U.S. Food and Drug Administration today approved Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS), a breathing disorder that affects premature infants.

27 Mar 2012

New analytical method predicts maturity in premature infants

Late gestation is a busy time for babies getting ready for life outside the womb, particularly for functions critical to life such as breathing and maintaining an adequate heartbeat. These two functions are connected in mature infants and healthy people throughout life, so measuring their level of connectedness can give doctors a cue about whether an infant is ready to head home or needs to remain in the care of the neonatal intensive care unit.

27 Mar 2012

First study to explore differential gender effects of secondhand smoke exposure

The negative health effects of early-life exposure to secondhand smoke appear to impact girls more than boys-particularly those with early-life allergic sensitization, according to new research from the University of Cincinnati (UC) College of Medicine.

27 Mar 2012